Search research articles
Contact Us
Filters
Showing results (1-10 of 11) with videos related to
Page
of 2
Sort By:
Bioinformatics (Oxford, England)
|
February 14, 2004
NetAffx Gene Ontology Mining Tool: a visual approach for microarray data analysis
Jill Cheng, Shaw Sun, Adam Tracy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 30, 2019
Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer
Sophia C Kamran, Jochen K Lennerz, Claire A Margolis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 6, 2019
Genomic Evolutionary Patterns of Leiomyosarcoma and Liposarcoma
Ali Amin-Mansour, Suzanne George, Stefano Sioletic, et al.
Blood Advances
|
December 21, 2018
Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance)
Gail J Roboz, Sumithra J Mandrekar, Pinkal Desai, et al.
Science (New York, N.Y.)
|
January 6, 2018
Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma
Diana Miao, Claire A Margolis, Wenhua Gao, et al.
Nature Genetics
|
August 29, 2018
Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors
Diana Miao, Claire A Margolis, Natalie I Vokes, et al.
Nature
|
June 29, 2017
Recurrent and functional regulatory mutations in breast cancer
Esther Rheinbay, Prasanna Parasuraman, Jonna Grimsby, et al.
Nature Medicine
|
December 4, 2019
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
David Liu, Bastian Schilling, Derek Liu, et al.
Nature Medicine
|
June 21, 2020
Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
David Liu, Bastian Schilling, Derek Liu, et al.
Elife
|
March 13, 2019
Renal medullary carcinomas depend upon <i>SMARCB1</i> loss and are sensitive to proteasome inhibition
Andrew L Hong, Yuen-Yi Tseng, Jeremiah A Wala, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 11) with videos related to
Sort By:
Page
of 2
Bioinformatics (Oxford, England)
|
February 14, 2004
NetAffx Gene Ontology Mining Tool: a visual approach for microarray data analysis
Jill Cheng, Shaw Sun, Adam Tracy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 30, 2019
Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer
Sophia C Kamran, Jochen K Lennerz, Claire A Margolis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 6, 2019
Genomic Evolutionary Patterns of Leiomyosarcoma and Liposarcoma
Ali Amin-Mansour, Suzanne George, Stefano Sioletic, et al.
Blood Advances
|
December 21, 2018
Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance)
Gail J Roboz, Sumithra J Mandrekar, Pinkal Desai, et al.
Science (New York, N.Y.)
|
January 6, 2018
Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma
Diana Miao, Claire A Margolis, Wenhua Gao, et al.
Nature Genetics
|
August 29, 2018
Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors
Diana Miao, Claire A Margolis, Natalie I Vokes, et al.
Nature
|
June 29, 2017
Recurrent and functional regulatory mutations in breast cancer
Esther Rheinbay, Prasanna Parasuraman, Jonna Grimsby, et al.
Nature Medicine
|
December 4, 2019
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
David Liu, Bastian Schilling, Derek Liu, et al.
Nature Medicine
|
June 21, 2020
Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
David Liu, Bastian Schilling, Derek Liu, et al.
Elife
|
March 13, 2019
Renal medullary carcinomas depend upon <i>SMARCB1</i> loss and are sensitive to proteasome inhibition
Andrew L Hong, Yuen-Yi Tseng, Jeremiah A Wala, et al.
Page
of 2